Thermo Fisher and Celltrio are introducing a new automation platform to address critical scale-up challenges in biotherapeutics.
Thermo Fisher Scientific and Celltrio announced on Feb. 6, 2022 their collaboration to bring a fully automated cell culture system to biotherapeutics customers. The collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the critical unmet market need for high-throughput automated cell line culturing and maintenance.
Thermo Fisher will also immediately take on exclusive responsibility for sales, installation, and support of the RoboCell system in Europe. Celltrio’s RoboCell systems distributed in Europe will now use Momentum software for work scheduling and date management.
“Cell line scale-up challenges have long stifled the full potential of biotherapy research. While researchers have been able to automate some aspects of cell line production, full automation has been well out of reach,” said Hansjoerg Haas, senior director and general manager, laboratory automation, Thermo Fisher Scientific, in a company press release. “By collaborating with Celltrio, we’re bringing together the capabilities that make fully automated cell line culturing a reality. With the ability to effectively scale processes, biotherapeutics customers can focus on getting their innovative therapies to patients, paving the way to a better, healthier world.”
Source: Thermo Fisher
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.